Program
HRS-6208
A development code. Also written as “HRS-6208 capsules”.
In Jiangsu HengRui Medicine's pipeline, CDK7
. Its studies are mostly in Prostatic Neoplasms, led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Aug 21, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 22 open or running | phase 2since Aug 21, 2024 | Aug 21, 2024 | Dec 2026phase 2 · NCT06568094 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-6208
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2024First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06568094 · 100 planned · China
- Dec 6, 2024Phase 1 study in Solid TumorsNCT06727812 · 206 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Prostatic NeoplasmsNCT06568094
- Aug 2027Primary completion: phase 1 study in Solid TumorsNCT06727812
TargetBeta
“CDK7”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06727812Solid Tumors · China | 1 | Recruiting | Aug 2027 | 206 |
| NCT06568094Prostatic Neoplasms · China | 2 | Recruiting | Dec 2026 | 100 |
How it is read
Names in the registry
- “HRS-6208 capsules”, 1 entry
- “HRS-6208”, 1 entry
Codes read as this program: HRS6208.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.